Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

INITIATE-studien: Initiering av nikotinavhengighetsbehandling for røykere innlagt på legevakt (INITIATE)

30. oktober 2026 oppdatert av: Ottawa Heart Institute Research Corporation

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

1208

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Ontario
      • Ottawa, Ontario, Canada
        • Rekruttering
        • University of Ottawa Heart Institute
        • Ta kontakt med:
      • Ottawa, Ontario, Canada
        • Rekruttering
        • Civic Hospital
        • Ta kontakt med:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Telefonnummer: 6137985555,17023
          • E-post: vthirug@toh.ca
      • Ottawa, Ontario, Canada
        • Rekruttering
        • General Hospital
        • Ta kontakt med:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Telefonnummer: 6137985555,17023
          • E-post: vthirug@toh.ca
      • Ottawa, Ontario, Canada
        • Rekruttering
        • Riverside Hospital
        • Ta kontakt med:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Telefonnummer: 6137985555,17023
          • E-post: vthirug@toh.ca

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Current daily smoker (smokes ≥ 5 cigarettes per day);
  • ≥ 18 years of age (the age of majority in Ontario);
  • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
  • Able to read and understand English or French;
  • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  • Available and willing to participate in follow-up assessments over the next 12 months;
  • Has access to a telephone or computer;
  • Able to provide informed consent

Exclusion Criteria:

  • Currently participating in this or another smoking cessation study;
  • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
  • Pregnant, planning to become pregnant over the next year, or breastfeeding;
  • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
  • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
  • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Quit Card Intervention (QCI)

Study intervention group.

The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.

Ingen inngripen: Usual Care (UC)

Study control group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Smoking Abstinence
Tidsramme: 26 weeks (6 months) after study enrollment

Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test

26 weeks (6 months) after study enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prolonged Abstinence
Tidsramme: 4, 26, and 52 weeks after study enrollment

Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Point Prevalence Abstinence
Tidsramme: 4, and 52 weeks after study enrollment

Point prevalence smoking abstinence, at 4, and 52 weeks

4, and 52 weeks after study enrollment
Smoking Reduction
Tidsramme: 4, 26, and 52 weeks after study enrollment

Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Number of Quit Attempts
Tidsramme: 4, 26, and 52 weeks after study enrollment

Number of quit attempts since study entry, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cessation Medication and/or E-cigarette Use
Tidsramme: 4, 26, and 52 weeks after study enrollment

Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Use of Behavioural Supports
Tidsramme: 4, 26, and 52 weeks after study enrollment

Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health-Related Quality of Life
Tidsramme: 52 weeks after study enrollment

Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

52 weeks after study enrollment
Health Services Outcomes - ED visits
Tidsramme: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Hospital Admissions
Tidsramme: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Deaths
Tidsramme: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cost-Effectiveness Ratios
Tidsramme: 52 weeks after study enrollment

Cost-effectiveness ratios related to health services at 52 weeks

52 weeks after study enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. april 2022

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

7. oktober 2019

Først innsendt som oppfylte QC-kriteriene

13. november 2019

Først lagt ut (Faktiske)

14. november 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere